ahlam1399
08-06-2015, 11:44 AM
AstraZeneca widens cancer push with up to $500 mln Heptares deal
LONDON, Aug 6 (Reuters) - AstraZeneca expanded its push into cancer immu**therapy on Thursday by striking a deal potentially worth more than $500 million with Sosei's biotech unit Heptares, giving it rights to an experimental treatment.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/48c08de7/sc/7/mf.gif?resize=1%2C1 http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=xTzaD4B5sXk:KWDqZFauNAg:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=xTzaD4B5sXk:KWDqZFauNAg:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=xTzaD4B5sXk:KWDqZFauNAg:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=xTzaD4B5sXk:KWDqZFauNAg:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=xTzaD4B5sXk:KWDqZFauNAg:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/xTzaD4B5sXk
LONDON, Aug 6 (Reuters) - AstraZeneca expanded its push into cancer immu**therapy on Thursday by striking a deal potentially worth more than $500 million with Sosei's biotech unit Heptares, giving it rights to an experimental treatment.
http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/48c08de7/sc/7/mf.gif?resize=1%2C1 http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=xTzaD4B5sXk:KWDqZFauNAg:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=xTzaD4B5sXk:KWDqZFauNAg:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=xTzaD4B5sXk:KWDqZFauNAg:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=xTzaD4B5sXk:KWDqZFauNAg:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=xTzaD4B5sXk:KWDqZFauNAg:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/xTzaD4B5sXk